ZAP Surgical Systems, Inc., a leader in non-invasive robotic brain surgery, has closed a $36 million financing round led by Catalio Capital Management, with continued participation from Baheal, its strategic partner in China. The investment underscores growing confidence in the company's ZAP-X Gyroscopic Radiosurgery platform and its potential across neuro-oncology and neuropsychiatric care. The capital will support global expansion, increased production capacity, and clinical research aimed at treating psychiatric disorders.
Financing and Strategic Backing
Catalio Capital Management led the round, reflecting strong investor confidence in ZAP's technology and commercial momentum. Baheal, which serves as ZAP's strategic partner in China, also continued its support. The funding will help healthcare institutions across academic medical centers, community hospitals, and physician-led practices adopt the ZAP-X platform.
Catalio Capital Management's Role
Catalio Capital Management is a New York-based investment firm focused on innovative healthcare and AI investing with over $2 billion in assets under management. Nicholas von Guionneau, M.D., Ph.D. at Catalio will join ZAP's Board as an Observer. He said intelligent robotics can lower cost structures and elevate care standards in developed nations and underserved emerging markets.
ZAP-X Platform and Commercial Momentum
ZAP recently achieved a major commercial milestone with the shipment of its 50th ZAP-X system, and the company is now scaling production capacity to meet increasing global demand. The platform has treated nearly 10,000 patients worldwide, generating clinical evidence that supports its precision and speed for brain tumors and other neurological conditions. The new capital will advance the deployment of this vault-free radiosurgery technology across a range of healthcare settings.
Radiomodulation and Neuropsychiatric Research
Beyond established neuro-oncology indications, ZAP and its collaborators have spent more than a decade studying precisely targeted low dose ionizing radiation, now referred to as radiomodulation. This research has demonstrated neuromodulatory effects in multiple mammalian brain models. Preliminary data from a first-in-human pilot study on severe treatment-resistant depression has encouraged broader multi-center clinical trials for psychiatric disorders such as treatment-resistant depression and addiction.
Leadership Perspectives
John R. Adler, M.D., Founder and CEO of ZAP Surgical Systems, welcomed Catalio as a new capital partner and stressed the importance of mission-aligned investors. He predicted that as understanding of the brain deepens, neuroscience will see unprecedented therapeutic breakthroughs over the coming decade. Adler also said Baheal has been instrumental in advancing ZAP's presence in China, while Catalio's strategic support will be invaluable for accelerating adoption in the United States.
Company and Technology Background
ZAP Surgical Systems was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy and TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. The company introduced ZAP-X Gyroscopic Radiosurgery, which it describes as the world's first vault-free radiosurgery platform. ZAP continues to expand its global footprint in neuro-oncology while advancing radiomodulation as an emerging treatment approach.
Future Outlook
The financing positions ZAP to scale non-invasive, cost-effective brain therapy to a broader patient population. With nearly 10,000 patients treated and production capacity increasing, the company expects to widen access across leading academic medical centers and community hospitals. Its dual focus on oncology and psychiatric applications may open new markets in mental health treatment.
With this $36 million financing round, ZAP Surgical Systems is positioned to broaden access to its vault-free, non-invasive radiosurgery technology on a global scale. The company's dual focus on neuro-oncology and emerging psychiatric applications reflects a growing recognition that precise, robotics-driven brain therapy can address both tumors and mental health conditions. As clinical evidence expands and production scales, ZAP aims to make advanced brain treatment more accessible and cost-effective.